Two Sigma Securities LLC Buys Shares of 15,943 ESSA Pharma Inc. (NASDAQ:EPIX)

Two Sigma Securities LLC bought a new position in ESSA Pharma Inc. (NASDAQ:EPIX) (TSE:EPI) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 15,943 shares of the company’s stock, valued at approximately $29,000.

Several other hedge funds also recently modified their holdings of EPIX. Altium Capital Management LLC acquired a new stake in ESSA Pharma in the 4th quarter worth approximately $2,556,000. Marshall Wace LLP acquired a new stake in shares of ESSA Pharma in the fourth quarter worth $324,000. XTX Topco Ltd acquired a new stake in shares of ESSA Pharma in the fourth quarter worth $67,000. Aldebaran Capital LLC bought a new stake in shares of ESSA Pharma during the 4th quarter worth $712,000. Finally, Lepercq Multi Asset Fund bought a new position in ESSA Pharma in the 4th quarter worth $54,000. Institutional investors and hedge funds own 75.12% of the company’s stock.

ESSA Pharma Price Performance

EPIX stock opened at $1.73 on Friday. The stock has a market capitalization of $76.79 million, a price-to-earnings ratio of -2.51 and a beta of 1.69. The company has a 50-day moving average of $1.64 and a two-hundred day moving average of $1.99. ESSA Pharma Inc. has a 52-week low of $1.40 and a 52-week high of $7.88.

ESSA Pharma (NASDAQ:EPIX) (TSE:EPI) last released its earnings results on Tuesday, February 11th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.01). Equities analysts expect that ESSA Pharma Inc. will post -0.42 EPS for the current fiscal year.

About ESSA Pharma

ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company’s lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer.